[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hadassah Medical Organization\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":635},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,50,77,104,130,163,187,207,229,252,278,312,335,360,383,409,436,459,480,500,526,546,563,580,606],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100625929","intraoperative-bupivacaine-injection-to-reduce-acute-and-chronic-pain-after-tvttvt-o-surgery-randomized-double-blind-trial-100625929",false,"NCT07429019","Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT\u002FTVT-O Surgery. Randomized Double-Blind Trial","Reduction of Post-surgery Pelvic Pain by Bupivacaine Injection During TVT\u002F TVT-O Procedure","PAIN-TVT","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Scheduled to undergo vaginal surgery including TVT or TVT-O procedure for stress urinary incontinence\n* Able and willing to provide written informed consent\n* Willing to complete postoperative follow-up assessments for at least 6 months\n\nExclusion Criteria:\n\n* Planned concomitant abdominal, laparoscopic, or robotic surgery\n* Pre-existing chronic pelvic pain\n* Diagnosis of fibromyalgia\n* Diagnosis of endometriosis\n* Inability to complete follow-up assessments\n* Inability to provide informed consent","FEMALE","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized, double-blind controlled trial will evaluate whether intraoperative injection of bupivacaine at the sling insertion site reduces postoperative pelvic and thigh pain in women undergoing TVT or TVT-O surgery for stress urinary incontinence. Women aged 18 years and older scheduled for vaginal surgery including a mid-urethral sling procedure will be randomly assigned to receive either 0.5% bupivacaine or saline injection at the surgical site at the end of the procedure.\n\nPostoperative pain will be assessed using the Numerical Rating Scale (NRS) within 24 hours after surgery, at one month, and at least six months postoperatively. The study will also evaluate opioid consumption and examine the relationship between early postoperative pain and the development of chronic postsurgical pain. The results may help determine whether local anesthetic injection during sling surgery can improve short- and long-term pain outcomes.",[28,29,30,31],"Pain After Surgery","PSP","Chronic Pain Syndrome","Local Anesthesia Infiltration",[33,34,35,36,37],"TVT","TVTO","Mid Urethral Sling","pain","chronic pain syndrom","NOT_YET_RECRUITING","2026-06-20",{"date":41,"type":42},"2026-06-23","ACTUAL",{"date":44,"type":22},"2026-07-01",{"date":46,"type":22},"2027-10-01",{"name":48,"class":49},"Hadassah Medical Organization","OTHER",{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100626032","obstetric-risk-assessment--cesarean-delivery-in-labor-estimation-using-artificial-intelligence-100626032","NCT07430358","Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence","Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence Trial (ORACLE-AI)","ORACLE-AI","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of consent\n* Able and willing to provide written informed consent\n* Nulliparous (no prior birth ≥ 24 weeks' gestation)\n* Singleton live pregnancy\n* Cephalic (vertex) fetal presentation\n* Gestational age ≥ 37+0 weeks\n* Admitted to the labor ward in labor (cervical dilation ≥ 3 cm with regular contractions) or undergoing induction or augmentation of labor with intent to proceed to vaginal delivery\n* Planned trial of labor (no scheduled or elective cesarean delivery)\n* Receiving intrapartum care at Hadassah-Hebrew University Medical Center, Mount Scopus campus\n\nExclusion Criteria:\n\n* Planned or elective cesarean delivery prior to labor admission\n* Multifetal gestation\n* Non-cephalic fetal presentation\n* Gestational age \\\u003C 37+0 weeks\n* Major fetal anomaly expected to affect labor or neonatal management\n* Contraindication to vaginal delivery (e.g., placenta previa, invasive placentation, prior uterine surgery precluding labor)\n* Category III fetal heart rate tracing on admission requiring immediate delivery\n* Maternal hemodynamic instability or other life-threatening condition necessitating urgent surgical or critical-care intervention\n* Inability to provide informed consent due to cognitive impairment, intoxication, or other incapacity\n* Concurrent participation in another interventional obstetric study that could confound outcomes or increase risk",true,{"count":60,"type":22},400,[25],"ORACLE-AI is a single-center, open-label, randomized clinical trial comparing primiparous women managed with a real-time machine-learning dashboard against a concurrent control group receiving standard intrapartum care. Participants are randomized 1:1 at the onset of labor. The intervention group has the AI dashboard visible in their electronic health record, while the control group does not. The primary hypothesis is that the use of continuous AI-based risk estimates will be non-inferior to standard care in terms of unplanned cesarean\\–delivery rates (uCD), with potential secondary benefits in maternal and neonatal outcomes.",[64,65,66],"Labor, Obstetric","Pregnancy","Cesarean Section Rate","RECRUITING","2026-05-20",{"date":70,"type":42},"2026-05-22",{"date":72,"type":22},"2026-05-19",{"date":74,"type":22},"2027-04-30",{"name":48,"class":49},1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":76},"100639303","the-computerized-retraining-and-functional-treatment---group-intervention-100639303","NCT07591857","The Computerized Retraining and Functional Treatment - Group Intervention","The Computerized Retraining and Functional Treatment: Effectiveness-implementation Hybrid Trial of Group Teleintervention Among Breast Cancer Survivors With Cognitive Impairment","CRAFT-G","Inclusion Criteria:\n\n1. women, 18 years old and older\n2. A subjective concern about declines in cognitive functioning related to a diagnosis of breast cancer and\u002For cancer related treatment\n3. Objective cognitive decline with no dementia (19\\\u003CMOCA)\n4. 6 months or more after completion of an active treatment for cancer\n5. Daily access to the internet and sufficient basic skills to operate a computer\n\nExclusion Criteria:\n\n* Unstable psychiatric or other health condition according to participants' self-report and medical file.",{"count":86,"type":22},48,[25],"The goal of this clinical trial is to examine the efficacy of a novel, remotely-applied group intervention, Cognitive Retraining and Functional Treatment Group (CRAFT-G), designed to improve cognitive function, mental health and functional outcome in breast cancer survivors (BCS) with Cancer-Related Cognitive Impairment (CRCI) while simultaneously collecting data on the barriers and facilitators of implementation in clinical settings. The main question it aims to answer is:\n\nWe hypothesize that participants receiving CRAFT-G will show gains in mental health, cognitive and daily function, and that the CRAFT-G benefits will endure for three months following treatment completion.\n\nParticipants assigned to the waitlist control will crossover to the CRAFT-G intervention group after 6 weeks.\n\nParticipants will ask to complete CRAFT-G intervention, which include:\n\n* Six remote group sessions (1.5hr each)\n* Between the sessions, participants will be guided to complete CRCI-specific computerized cognitive training (CCT) 3 times per week delivered using dedicated app.\n* Psychoeducation materials Assessment will take place in 3 time points: before intervention (frontal meeting for baseline assessment), post intervetion and 3 months post intervention.\n\nThe study will be conducted to explore implementation barriers and facilitators. This will be done by endline qualitative interviews with the participants' research group.",[90,91],"Cancer Related Cognitive Impairment","Breast Cancer Survivor",[93,94,95],"Tele-rehabilitation","Cognitive training","Group therapy","2026-05-11",{"date":98,"type":42},"2026-05-18",{"date":100,"type":42},"2025-11-16",{"date":102,"type":22},"2028-06",{"name":48,"class":49},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":58,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100069899","determinants-of-warfarin-metabolism-100069899","NCT00162474","Determinants of Warfarin Metabolism","Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism.","Inclusion Criteria:\n\n* Age range of 20-50 years old\n* The absence of significant disease states\n\nExclusion Criteria:\n\n* Known hypersensitivity to warfarin or phenytoin\n* Known hepersensitivity to penicillins or cephalosporins (Dicloxacillin part)\n* The presence of significant disease states\n* Regular use of drugs (including birth control pills)","ALL","20 Years","50 Years",{"count":115,"type":22},1000,[25],"The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin.\n\nThe present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.",[119],"Healthy",[121],"Healthy Volunteers","2026-04-16",{"date":124,"type":42},"2026-04-21",{"date":126,"type":42},"2003-09",{"date":128,"type":22},"2030-12",{"name":48,"class":49},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":76},"100630218","virtual-reality-intervention-to-reduce-pain-in-women-undergoing-elective-oocyte-cryopreservation-100630218","NCT07484815","Virtual Reality Intervention to Reduce Pain in Women Undergoing Elective Oocyte Cryopreservation","The Effectiveness of Virtual Reality for Pain Reduction in Women Undergoing Elective Oocyte Cryopreservation: A Randomized Controlled Trial","OPU-VR","Inclusion Criteria:\n\n* Women undergoing elective oocyte retrieval for fertility preservation.\n* Age 18-45 years.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Use of pain relief, anti-anxiety, or antidepressant medications prior to the intervention.\n* Any condition for which VR use is not recommended, including:\n\n  * History of seizures\n  * Sensitivity to flashing light or motion\n  * Migraine headaches\n  * Predisposition to nausea or dizziness (e.g., vertigo)\n* Any injury to the eyes, face, or neck limiting use of the VR device, including blindness.","45 Years",{"count":140,"type":22},100,[25],"This randomized controlled study evaluates whether exposure to relaxing virtual reality (VR) scenery prior to oocyte retrieval can reduce pain in women undergoing elective oocyte cryopreservation.\n\nMany women experience discomfort before and after oocyte retrieval. Virtual reality has been shown to reduce pain in various medical settings by providing distraction and relaxation.\n\nIn this study, participants are randomly assigned to receive either routine care alone or routine care combined with a VR-based relaxation intervention while waiting for the procedure.\n\nPain is assessed using validated questionnaires and standardized scales before and after oocyte retrieval.\n\nThe results of this study may help determine whether VR can serve as a simple, safe, and non-pharmacological method to improve patient comfort during elective egg freezing.",[144,145],"Procedure-Related Pain","Acute Pain",[147,148,149,150,151,152,153,154],"Virtual Reality","Oocyte Retrieval","Pain Management","Fertility Preservation","Non-Pharmacological Intervention","Reproductive Medicine","Patient Comfort","Elective Oocyte Cryopreservation","2026-03-18",{"date":157,"type":42},"2026-03-20",{"date":159,"type":42},"2024-11-05",{"date":161,"type":22},"2026-12",{"name":48,"class":49},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":58,"sex":111,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":76},"100599087","phase-1-safety-and-psychological-effects-of-psilocybin-and-d-serine-formulation-in-healthy-volunteers-100599087","NCT07079930","Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","Inclusion Criteria:\n\n1. Aged 25-60 years, male or female.\n2. Medically healthy, as confirmed by a comprehensive clinical assessment.\n3. Written informed consent provided.\n\nExclusion Criteria:\n\n1. History of any Axis 1 psychiatric disorder requiring pharmacotherapy such as schizophrenia, schizoaffective disorder, any other psychotic disorder, bipolar disorder, as well as non-psychotic disorders such as generalized anxiety disorder, major depressive disorder, obsessive-compulsive disorder, posttraumatic stress disorder.\n2. Family history (among first-degree relatives) of schizophrenia, bipolar disorder, or other psychotic disorder\n3. History of cardiovascular disorders.\n4. Pregnant or breastfeeding women or women of childbearing age not using effective contraception.\n5. Use of psilocybin or other psychedelic compound in the 12 months preceding the study\n6. Use of medications that interact with psilocybin or D-Serine.\n7. Positive urinary drug screening.","25 Years","60 Years",{"count":172,"type":22},10,[174],"PHASE1","The goal of this open-label, dose-escalation, prospective study is to evaluate the safety and psychological effects of a Psilocybin and D-Serine formulation in healthy volunteers.\n\nThe main objectives are:\n\n1. To assess the psychological and physiological effects of psilocybin administered with D-Serine in healthy adults.\n2. To determine whether D-Serine modulates or attenuates the psychedelic effects of psilocybin.\n3. To evaluate the safety and tolerability of psilocybin and D-Serine co-administration.\n\nStudy population includes: 10 healthy male or female volunteers aged 25-60 years with no history of psychiatric or major medical disorders and no current evidence of such disorders.\n\nThe study includes two cohorts. The first cohort of 5 participants will receive 15 mg of Psilocybin and 5 g of D-Serine. Safety data will be collected and submitted in an interim report to the Ethics Committee. If no safety concerns arise, the second cohort will receive an increased dose of 25 mg of Psilocybin and 7 g of D-Serine to help determine the optimal dose for a future Phase IIa clinical trial.",[121],[178],"psilocybin D-Serine healthy volunteers","2026-02-03",{"date":181,"type":42},"2026-02-05",{"date":183,"type":42},"2025-12-11",{"date":185,"type":22},"2027-02",{"name":48,"class":49},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100623202","the-influence-of-patient-use-of-artificial-intelligence-on-doctor-patient-interaction-and-clinical-outcomes-in-endometriosis-consultations-100623202","NCT07393568","The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometriosis Consultations","Inclusion Criteria:\n\n* Women aged ≥18.\n* Attending clinic for endometriosis-related complaints.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Cognitive impairment or psychiatric conditions that affect communication or the ability to provide informed consent",{"count":194,"type":22},94,"OBSERVATIONAL","Generative artificial intelligence (AI), including large language models such as ChatGPT, Gemini, and Copilot, is increasingly used by patients to obtain medical information and prepare for clinical encounters. Although these tools often provide guideline-consistent information, their responses may be incomplete, inaccurate, or lack personalization, potentially influencing patient expectations and clinical interactions. The impact of patient AI use on satisfaction, adherence, and physician-patient communication remains poorly understood.\n\nThis prospective comparative study will evaluate the effects of patient AI use prior to gynecologic consultations for endometriosis. Women attending a specialized endometriosis clinic will be categorized as AI users or non-users based on their preparation for the visit. Patient-reported outcomes, including satisfaction, expectations, adherence to physician recommendations, and pain during physical examination, will be assessed using validated questionnaires and visual analogue scales. Physicians, blinded to AI use, will independently assess patient engagement, trust, and compliance. Visit duration will also be recorded.\n\nThe primary objective is to determine whether AI use affects patient satisfaction and adherence to treatment recommendations. Secondary objectives include evaluating physician-perceived interaction quality and concordance between AI-generated guidance and physician recommendations. Findings from this study will provide critical evidence on how AI influences patient behavior and clinical care in endometriosis, informing best practices for integrating AI-informed patients into routine clinical encounters.",[198],"Endometriosis","2026-01-31",{"date":201,"type":42},"2026-02-06",{"date":203,"type":22},"2026-02-01",{"date":205,"type":22},"2027-01-01",{"name":48,"class":49},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":111,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":76},"100618577","phase-1-study-of-naive-hbi0101-car-t-therapy-in-relapsedrefractory-multiple-myeloma-100618577","NCT07333430","Study of Naive HBI0101 CAR-T Therapy in Relapsed\u002FRefractory Multiple Myeloma","A Phase 1a\u002F1b Open-Label Study With Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n1. ≥18 years of age at the time of signing informed consent.\n2. Voluntarily signed informed consent form.\n3. Diagnosis of relapsed\u002Frefractory multiple myeloma (Parts 1a and 1b), with measurable disease at screening visit as follows:\n\n   Multiple Myeloma (at least one of the criteria below):\n   1. Serum M-protein greater or equal to 0.5 g\u002FdL.\n   2. Urine M-protein greater or equal to 200 mg\u002F24 h.\n   3. Serum free light chain (FLC) assay: involved FLC level greater or equal to 3 mg\u002FdL (30 mg\u002FL) provided serum FLC ratio is abnormal.\n   4. A biopsy-proven evaluable plasmacytoma\\*.\n   5. Bone marrow plasma cells \\> 10% of total bone marrow cells\\*.\n   6. Non secretory patient will be allowed provided they have measurable disease by PET-CT or bone marrow aspiration, as designated\\*.\n\n      * Results pre-dating the Screening visit by up to 28 days may be used to establish eligibility.\n4. R\u002FR MM subjects must have been exposed to at least three prior lines of therapy including the following agents:\n\n   1. proteasome inhibitor\n   2. immunomodulatory (IMiDs) agent\n   3. anti-CD38 antibody\n5. For part 1a: At least one of the following risk factors: a. Extra-medullary disease (EMD) - defined as a MM lesion that is not connected to a bone. b. previous exposure to an anti-BCMA therapy.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.\n7. Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.\n8. Recovery to ≤ Grade 2 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy, and toxicities that are irreversible and not expected to interfere with study treatment or pose safety concerns, per investigator judgement.\n9. Ability and willingness to adhere to the study visit schedule and all protocol requirements.\n10. For subjects with relapsed multiple myeloma who have previously undergone allogenic stem cell transplantation: no evidence of graft versus host disease after cessation of any immunosuppressive therapy for at least one month before recruitment to the study.\n\nExclusion Criteria:\n\n1. Contraindication to a study treatment\u002Fprocedure or is anticipated to receive treatment\u002Fprocedure that may preclude performance of study procedures.\n2. Known bulky central nervous system disease.\n3. Inadequate hepatic function defined by aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) \\> 2.5 x upper limit of normal (ULN) and\u002For direct bilirubin \\> 4x ULN.\n4. Inadequate renal function defined by estimated clearance of \\\u003C20(ml\u002Fmin).\n5. International ratio (INR) or partial thromboplastin time (PTT) \\> 2 x ULN, unless on a stable dose of anticoagulant for a thromboembolic event (provided this event is not an exclusion criteria).\n6. Inadequate bone marrow function defined by absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm3, platelet count \\\u003C 30,000 mm3, or hemoglobin \\\u003C 8 g\u002FdL. Subjects with absolute lymphocyte count \\\u003C 300 cells\u002Fmm3 may be excluded (due to potential challenges with producing CART), per investigator judgement.\n7. Left ventricular ejection fraction \\\u003C 40%.\n8. Ongoing treatment with chronic immunosuppressant such as cyclosporine or systemic steroids (physiological replacement doses of steroids are allowed up to 12 mg\u002Fm2\u002Fd hydrocortisone or equivalent)\n9. Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions.\n10. Known human immunodeficiency virus (HIV) positive status.\n11. Active Hepatitis B active infection (defined as HBS-antigen and HBV DNA positive) or Hepatitis C active infection (defined as anti-HCV and HCV RNA positive).\n12. Active CMV infection.\n13. Known history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months.\n14. Chronic atrial fibrillation with uncontrolled heart rate.\n15. Second primary malignancy that has required therapy in the last 2 years or is not in complete remission. This exclusion criterion does not exclude the following subjects: successfully treated non- metastatic basal cell or squamous cell skin carcinoma, or prostate cancer under control with hormonal therapy\n16. Subjects who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:\n\n    1. Have been on a stable dose of anticoagulation for \\\u003C 1 month (except for acute line insertion induced thrombosis.\n    2. Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days\n    3. Are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement).\n17. Pregnant or lactating women.",{"count":21,"type":22},[174],"A Phase 1a\u002F1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed\u002FRefractory Multiple Myeloma.",[218],"Relapsed\u002FRefractory Multiple Myeloma (MM)",[220],"Multiple Myeloma (MM)","2025-12-30",{"date":223,"type":42},"2026-01-12",{"date":225,"type":22},"2026-01-15",{"date":227,"type":22},"2030-12-01",{"name":48,"class":49},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":58,"sex":18,"minAge":169,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100535969","food-literacy-intervention---is-a-train-the-trainer-approach-feasible-and-effective-100535969","NCT06258733","Food Literacy Intervention - is a \"Train the Trainer\" Approach Feasible and Effective?","Food Literacy Intervention for Arab and Jewish Women in the Jerusalem Region - is a \"Train the Trainer\" Approach Feasible and Effective?","Inclusion Criteria:\n\n* Hebrew or Arabic literate women who are over 25 years old\n\nExclusion Criteria:\n\n* Women who do not meet inclusion criteria.",{"count":237,"type":22},480,[25],"Food literacy (FL) is the capability to make healthy food choices in different contexts, settings and situations. Although eating habits are shaped by different circumstances and skills, most nutrition programs focus on nutrition knowledge alone. Addressing factors such as competencies, self-efficacy and social norms enables sustainable positive change in nutrition behaviour. This study will assess a lay leader-led FL workshop to Arab and Jewish women from disadvantaged communities in the Jerusalem region, utilizing a train-the-trainer approach, and will compare the effectiveness and cost-effectiveness of a lay-led FL intervention to an expert-led intervention.",[241,242,243],"Lifestyle Risk Reduction","Health Behavior","Food Habits","2025-12-16",{"date":246,"type":42},"2025-12-17",{"date":248,"type":22},"2025-12",{"date":250,"type":22},"2027-02-01",{"name":48,"class":49},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":76},"100543383","effects-of-moderate-carbohydrate-consumption-on-metabolic-and-obstetric-outcomes-in-pregnant-women-with-insulin-treated-diabetes--a-randomized-controlled-trial-100543383","NCT06355154","Effects of Moderate Carbohydrate Consumption on Metabolic and Obstetric Outcomes in Pregnant Women With Insulin-treated Diabetes- A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Pregnant women with singleton pregnancies.\n\n  * Over 18 years old.\n  * Diagnosis of GDM- 3-h 100-g OGTT according to the American College of Obstetricians and Gynecologists supported by the American Diabetes Association, Or Diagnosis of type 1 or 2 diabetes before pregnancy, Or Diagnosis of early GDM by either OGTT in the first trimester or elevated blood glucose measurements in the fasting (above 95mg\u002Fdl) or the postprandial (above 140 mg\u002Fdl) state.\n  * Are already on or intended to start intensive insulin treatment (at leased 2 injections of insulin per day) or wear an insulin pump.\n  * Are willing to wear a continuous glucose monitoring system.\n  * BMI of 18.5-42 kg\u002Fm2 at the time of diagnosis.\n\nExclusion Criteria:\n\n* Individual with risk factors for:\n\n  * Placental insufficiency.\n  * Hypertension.\n  * Renal disease.\n  * Thrombophilia\n  * Rheumatologic disease.\n  * A history of preeclampsia, or fetal growth restriction (IUGR).\n  * Individuals with a history of preterm labor, or concomitant therapy with β-blockers or glucocorticoids.\n  * Individuals who smoke and\u002For consume any amount of alcohol during pregnancy.",{"count":259,"type":22},120,[25],"Diabetes during pregnancy increases maternal and fetal complications, necessitating optimal glycemic control. The standard care diet (SCD, ≥175g\u002Fday carbohydrate) lacks robust evidence, particularly for pregnancies requiring intensive insulin treatment (IIT). This RCT investigates whether a moderate carbohydrate diet (MCD, ≤120g\u002Fday) versus SCD improves glycemic control and alters metabolomic profiles in pregnant individuals on IIT.\n\nAims: To compare the efficacy and safety of a SCD versus MCD on glycemic control, metabolomic signatures, and pregnancy outcomes in pregnant individuals on IIT.",[263],"Diabetes in Pregnancy",[265,266,267,268,269],"Diabetes in pregnancy","Glycemic balance","Low Carbohydrates","Time in range","Ketosis","2025-09-29",{"date":272,"type":42},"2025-10-02",{"date":274,"type":42},"2024-05-28",{"date":276,"type":22},"2028-02-01",{"name":48,"class":49},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":111,"minAge":19,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":290,"conditions":291,"keywords":301,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":76},"100462046","phase-1-anti-ny-eso-1-tcr-gene-engineered-lymphocytes-given-by-infusion-to-patients-with-ny-eso-1--expressing-metastatic-cancers-100462046","NCT05296564","Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","A Phase I\u002FII Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","Inclusion Criteria:\n\n1. Have histologically or cytologically confirmed diagnosis of neoplasia\n2. Measurable (per RECIST v1.1 criteria) metastatic cancer or locally advanced refractory\u002Frecurrent malignancy not amenable to curative treatment. Lesions previously irradiated may be considered measurable only if growth has been documented since local treatment completion.\n3. The tumor expresses ESO as assessed immunohistochemistry of resected tissue. To this end, archived tumor tissue suitable for analysis must be available or re-biopsy performed on study. Tissue staining must encompass more than 10% of tumor section.\n4. Patients must have previously either (1) received at least first-line or second-line standard therapy for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease), intolerable or have recurred or (2) Recurred within 6 months of adjuvant systemic therapy known to be active also in the metastatic setting.\n5. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n6. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).\n7. Age ≥ 18 years and ≤ 70 years.\n8. Patient is able to understand and willing to sign a written informed consent.\n9. Clinical performance status of ECOG 0, 1 or 2.\n10. HLA-A\\*0201or A\\*0206 positive.\n11. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment.\n12. Women of child-bearing potential must have a negative pregnancy test.\n13. Serology: Seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n14. Hematology\n\n    * ANC \\> 1500\u002Fmm3 without the support of filgrastim\n    * WBC ≥ 3000\u002Fmm3\n    * Platelet count ≥ 100,000\u002Fmm3\n    * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n15. Chemistry\n\n    * Serum ALT\u002FAST ≤ 2.5 x ULN\n    * Creatinine clearance ≥40ml\u002Fmin\n    * Total bilirubin ≤ 1.5 mg\u002FdL, except in patients with Gilbert's Syndrome, who must have a total bilirubin \\\u003C 3.0 mg\u002FdL.\n    * INR \\\u003C 1.5\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n3. Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses\n4. Concurrent systemic steroid therapy, not including replacement therapy or treatment with prednisone up to 10mg daily or its equivalent. Or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention.\n5. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n6. Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months.\n7. Subjects unable to maintain normal oxygen saturation level in room air.\n8. Subjects who have had a venous thromboembolic event requiring anticoagulation and who meet any of the following criteria:\n\n   * Have been on a stable dose of anticoagulation for \\\u003C 1 month (except for acute line insertion induced thrombosis).\n   * Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days or are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement).\n9. Has a known additional malignancy within the last 3 years. Exceptions include early stage cancers (carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy).\n10. LVEF ≤ 40%\n11. Documented FEV1 ≤ 60% predicted tested in patients with:\n\n    * A prolonged history of cigarette smoking (≥ 20 pack-year smoking history, with cessation within the past two years).\n    * Symptoms of respiratory dysfunction.\n12. Patients who are at the time of study initiation receiving any other investigational agents.\n13. Carcinomatosis meningitis or other brain involvement exceeding that allowed above.\n14. Has received live vaccine within 30 days before the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.","70 Years",{"count":287,"type":22},3,[174,289],"PHASE2","A Phase I\u002FII Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers",[292,293,294,295,296,297,298,299,300],"Sarcoma, Synovial","Sarcoma,Soft Tissue","Melanoma Stage IV","Triple Negative Breast Cancer","Metastatic Cancer","Non Small Cell Lung Cancer","Bladder Urothelial Carcinoma","Neuroblastoma, Metastatic","Ovary Cancer",[302,303,304,305],"NY-ESO-1","TCR","adoptive transfer","retroviral transduction",{"date":272,"type":42},{"date":308,"type":42},"2022-04-01",{"date":310,"type":22},"2027-12-30",{"name":48,"class":49},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":111,"minAge":19,"maxAge":285,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":323,"conditions":324,"keywords":327,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":76},"100425212","phase-3-effect-of-cannabis-extract-on-acute-radicular-pain-and-on-analgesic-requirement-100425212","NCT04816994","Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement","Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement: A Double Blinded, Randomized, 24 Hours Follow-up Study","Inclusion Criteria:\n\n* Age 18 - 70 years\n* ASA 1 or 2\n* Acute Radicular Pain \\\u003C 12 weeks\n* Pain of VAS 6 or more\u002F VRS moderate or more\n* Radicular pain: Dermatomal pain that corresponds to physical exam and CT\u002FMRI in the last year\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 70 years\n* ASA 3 or more\n* Chronic radicular pain \\> 12 weeks\n* Past spine surgery\n* Intermittent Claudication due to Vascular Disease\n* Diagnosed Diabetic Neuropathy\n* Regular Cannabis use in past 6 months (more than once a week) OR once in last 2 weeks\n* Regular opioid use in past week (Targin, Percocet, Tramadol) (Equivalent to Oxycodone 20 mg\u002Fday or more)\n* Pregnancy or Lactating\n* Ischemic heart disease\n* Renal or hepatic failure\n* History of psychiatric illness\n* Cognitive impairment or inability to answer questions\n* Known allergy to opioids\n* Potential Loss to follow up",{"count":320,"type":22},200,[322],"PHASE3","Clinical evidence about the effects of cannabis in the management of acute pain is rather scarce, mostly consisting of case report-based opinions on adverse events during or after general anesthesia after smoking cannabis, experimental pain trials in healthy volunteers, and a few clinical trials using different drugs, dosages and routes of administration. It is difficult to draw strong conclusions from the available evidence, that may seem sometimes even contradictory, mainly due -the investigators believe- to the many sources of variability in the study designs (e.g.: heterogeneity of the study samples, underpowered, unblinding, lack of randomization, timing of the therapeutic intervention, different experimental pain models, inclusion of different kind of surgical pain, etc.). Nevertheless, expert's opinion after a critical review of the literature is that cannabis and cannabinoids may have a beneficial role in the management of acute pain, at least for a selected group of patients and through an appropriate therapeutic intervention.\n\nCannabis oil seem to be most suitable to our investigation. The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects. And will help treat acute radicular back pain and for renal colic.",[325,326],"Acute Radicular Back Pain","Cannabis",[328,326],"Acute radicular back pain",{"date":272,"type":42},{"date":331,"type":42},"2018-01-07",{"date":333,"type":22},"2025-12-31",{"name":48,"class":49},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":111,"minAge":4,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":76},"100201394","phase-1-modified-vaccine-for-high-risk-or-low-residual-melanoma-patients-100201394","NCT01898039","Modified Vaccine for High Risk or Low Residual Melanoma Patients","Allogeneic Vaccine Modified to Express HLA A2\u002F4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients - Phase I\u002FII Study.","Inclusion Criteria:\n\n1. Patients included in this protocol must carry one or more of the following tissue typing alleles: HLA-A2, -A24, -A33, -B35, -B49, -CW04\u002F12(04\u002F08). We estimate that 50% of melanoma patients will be eligible.\n2. Cutaneous malignant melanoma AJCC stage IIb (\\>4 mm) or IIc (ulcerated melanoma \\>4mm).\n3. Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post-surgical removal of lymph nodes.\n4. Metastatic melanoma AJCC stage IV, completely resected.\n5. Non-resectable metastatic melanoma of low burden disease and normal LDH who have undergone at least two treatment lines, including chemotherapy (DTIC, temodal, taxanes, platinum compounds), anti-CTLA-4 (ipilimumab) and B-RAF inhibitor if harboring the V600E BRAF mutation in their tumor.\n6. Non cutaneous malignant melanoma of respective stages including uveal and mucosal melanoma.\n7. Melanoma can be of either mutant or wild-type B-RAF.\n8. Karnofsky performance status \\> 80 (Normal activity with effort).\n9. No active cardio-respiratory disease.\n10. Not pregnant or nursing. Women must take contraceptives during the treatment period.Hematocrit \\>25% and WBC \\>3000.\n11. Informed consent of the patient.\n\nExclusion Criteria:\n\n1. Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior to protocol administration.\n2. Active brain metastases requiring corticosteroids.\n3. Concurrent malignancy (other than skin cancer, carcinoma in situ of cervix and early stage prostate cancer).\n4. Active serious infection.\n5. Allergy to penicillin.\n6. Patient's will to withdraw from the study at any stage.\n7. HIV and chronic hepatitis B and C carrier",{"count":343,"type":22},50,[174,289],"This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence. These patients will be treated with the A2\u002F4-1BBL melanoma vaccine, a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation. The hypothesis that drives the study states that the immune response against the cell line will also be effective against the residual tumor that may still be present in the body.",[347],"Malignant Melanoma",[349,350,351,352,353],"malignant melanoma","vaccine","cell line","high risk","residual disease",{"date":272,"type":42},{"date":356,"type":4},"2013-05",{"date":358,"type":22},"2027-04",{"name":48,"class":49},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":4,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":111,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":76},"100111950","phase-1-autologous-and-allogeneic-whole-cell-cancer-vaccine-for-metastatic-tumors-100111950","NCT00722228","Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","Inclusion Criteria:\n\n* One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney\n* Above 18 years of age\n* Failure of at least one chemotherapy protocol\n* Clinical performance status of ECOG 0,1\n* Absolute neutrophil count greater than 1000\u002Fmm3\n* Serum ALT\u002FAST less than three times the upper limit of normal\n* Serum creatinine less than or equal to 1.6 mg\u002Fdl.\n* Must be able to understand and sign the Informed Consent document\n\nExclusion Criteria:\n\n* Below 18 years of age\n* Women who are pregnant\n* Life expectancy of less than three months",{"count":343,"type":22},[174,289],"This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his\u002Fher immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.",[370,371,372,373,374,375,376],"Colorectal Cancer","Ovarian Cancer","Gastric Cancer","Breast Cancer","Lung Cancer","Kidney Cancer","Melanoma",{"date":272,"type":42},{"date":379,"type":42},"2008-07",{"date":381,"type":22},"2027-01",{"name":48,"class":49},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":111,"minAge":19,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":287},"100574703","phase-4-zoledronic-acid-for-the-prevention-of-tdf-sparing-art-induced-bone-mass-density-loss-in-treatment-naive-hiv-positive-individuals-100574703","NCT06762730","Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals","A Single Dose Intravenous Administration of Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals - a Prospective, Multicenter, Open-label, Randomized Control Trial","Inclusion Criteria:\n\n* Adults over age of 18 years old of any gender, social, religious or racial background.\n* Confirmed positive result for HIV infection.\n\nExclusion Criteria:\n\nPatients who received previous pharmacological agents for the prevention of HIV infection.\n\n* Women who are pregnant, lactating or those who plan to become pregnant within the trial timeframe.\n* Past history of severe drug-induced reaction (including atypical femur fractures or osteonecrosis of the jaw) or documented hypersensitivity to a bisphosphanate agent.\n* Patients with untreated hypocalcemia at screening.\n* Severe dental status",{"count":391,"type":22},110,[393],"PHASE4","The goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV.\n\nThe main questions it aims to answer are:\n\n1. Is bone mass deterioration is significant even with the new medication currently used to treat HIV?\n2. Can one dose of Zolendric acid protect from deterioration of bone mass.\n\nResearchers will compare one dose of zolendric acid to follow-up only\n\nParticipant will:\n\n1. Provide blood samples for bone markers before antiviral treatment initiation and at 6M,12M,24M and 48M after treatment initiation\n2. Perform DXA scan soon after antiviral treatment initiation and after 12M ,24 M and 48 months\n3. Half of the patients with moderate reduction in bone mass will be treated with one dose of zolendric acid in the clinical trial, the other participants will be followed without intervention.\n4. Patients with substantial osteoporosis will be treated according to standard of care by their HMO, but will continue followup in the study.",[396,397],"HIV Infected Individuals","Osteopenia",[397,399,400],"zoledronic acid","HIV naïve","2025-09-13",{"date":403,"type":42},"2025-09-18",{"date":405,"type":42},"2024-12-09",{"date":407,"type":22},"2032-12-01",{"name":48,"class":49},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":58,"sex":111,"minAge":417,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":76},"100598865","the-effects-of-ttns-ttns-combined-with-phus-and-conventional-therapy-with-phus-in-the-treatment-of-pfc-100598865","NCT07077044","The Effects of TTNS, TTNS Combined With PHUS, and Conventional Therapy With PHUS in the Treatment of PFC.","Transcutaneous Electrical Nerve Stimulation in Children With Functional Constipation Monitored by Pocket-sized Point-of-care Ultrasound.","constipation","Inclusion Criteria Children aged 4 to 14 years\n\nClinical diagnosis of functional constipation (FC), with no identifiable organic or anatomical cause (e.g., endocrine, metabolic, anatomical, or neuromuscular dysfunction)\n\nFC diagnosis established according to Rome IV criteria\n\nNo additional tests required to confirm eligibility\n\nAbility to complete daily diaries and TTNS sessions (by participant or caregiver)\n\nFailure of conservative medical treatment (including toilet training and laxatives) after at least three months\n\nExclusion Criteria Malformations of the digestive system and rectal anatomical anomalies (e.g., large intestinal atresia\u002Fstenosis, Hirschsprung's disease, congenital anorectal anomalies)\n\nNeurological or psychiatric disorders (e.g., cerebral palsy, spina bifida, intellectual disability, anorexia nervosa)\n\nMajor cognitive impairment\n\nMetabolic conditions (e.g., diabetes mellitus, diabetes insipidus, scurvy, phenylketonuria)\n\nEndocrine disorders (e.g., hypothyroidism)\n\nCardiac conditions (e.g., heart disease, arrhythmias, presence of pacemaker or ventriculoperitoneal shunt) due to possible interference with electrical stimulation\n\nHistory of thoracic or abdominal surgery\n\nPresence of skin lesions in the area of electrode application\n\nPresence of active electronic implants","4 Years","14 Years",{"count":420,"type":22},64,[25],"This study is a randomized, controlled trial designed to evaluate the effects of transcutaneous tibial nerve stimulation (TTNS), TTNS combined with pocket-sized handheld ultrasound (PHUS), and conventional therapy with PHUS on children with functional constipation (FC). Participants will be stratified into three intervention arms (n=20 per group).\n\nFC will be defined based on the Rome IV diagnostic criteria, in the absence of organic or anatomical causes. Participants will be between 4 and 14 years old and will have experienced failure of conservative treatment for at least three months prior to enrollment.\n\nThe primary outcomes include changes in rectal ultrasound parameters and symptom severity scores. Ultrasound assessments will be conducted by trained clinicians using standardized protocols. Monitoring for adverse events will be performed throughout the intervention phase. Safety considerations include predefined exclusion criteria, such as underlying neurological, metabolic, or cardiac conditions.",[424,425],"Constipation","Constipation - Functional",[427],"children with functional constipation","2025-07-20",{"date":430,"type":42},"2025-07-22",{"date":432,"type":42},"2024-02-21",{"date":434,"type":22},"2026-02-25",{"name":48,"class":49},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":58,"sex":111,"minAge":4,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":76},"100496836","vaccinations-and-people-with-disabilities-100496836","NCT05749419","Vaccinations and People With Disabilities","Questionnaires and Focus Groups Based Quantitative & Qualitative Study of Vaccine Hesitancy and Confidence Among At-risk and Marginalized Populations: Persons With Special Needs, Intellectual Disabilities and Congenital Anomalies","Inclusion Criteria:\n\n• Diagnosed children with disabilities, chronic diseases or congenital anomalies\n\nExclusion Criteria:\n\n* Undiagnosed children\n* Inadequate filled out questionnaires",{"count":115,"type":22},"The goal of this observational study is to learn about vaccinations hesitancy, delay or avoidance in children with chronic diseases, congenital anomalies or disabilities. The main questions it aims to answer are:\n\n• Attitudes of caregivers towards vaccinating their children, obstacles that postpone vaccinations, and the status of vaccinations of these children.\n\nParticipants will fill out questionnaires and some will be included in focused groups for the qualitative part of the study.\n\nResearchers will compare the vaccinations status of the research group to their siblings' status as well as the published national records of vaccination compliance.",[446,447,448,449,450],"Vaccine Refusal","Compliance, Patient","Disability, Intellectual","Congenital Disorders","Pediatric Disorder","2025-04-01",{"date":453,"type":42},"2025-04-03",{"date":455,"type":42},"2023-07-01",{"date":457,"type":22},"2026-01",{"name":48,"class":49},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":58,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":76},"100550987","subcutaneous-lavage-in-cesarean-section-100550987","NCT06454227","Subcutaneous Lavage in Cesarean Section","Antiseptic Washing Prior to Skin Closure During Cesarean Delivery- a Randomized Control Trial","Inclusion Criteria:\n\n* pregnant women undergoing cesarean delivery\n\nExclusion Criteria:\n\n* pregnant women undergoing vaginal delivery",{"count":467,"type":22},600,[25],"The goal of this clinical trial is to learn if antiseptic washing prior to skin closure during cesarean section reduces rates of surgical site infection.\n\nintraoperative washing is a common practice in other surgical fields and several studies have shown efficacy in reducing postoperative infection rates. no randomized control trial has tested this intervention during cesarean section.\n\nThe main questions we aim to answer are:\n\nDoes subcutaneous antiseptic washing reduce the rates of surgical site infection? Does antiseptic washing improve scar healing? Does antiseptic washing reduce hospital stay, postpartum fever rates and readmission cases?\n\nResearchers will compare subcutaneous antiseptic washing to no intervention to see if surgical site infection rates reduce\n\nParticipants will:\n\nconsent to participate in the trial Visit the postpartum clinic 30 days after surgery",[471],"Surgical Site Infection","2025-03-17",{"date":474,"type":42},"2025-03-19",{"date":476,"type":42},"2024-09-22",{"date":478,"type":22},"2028-12-01",{"name":48,"class":49},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":58,"sex":111,"minAge":19,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":487,"conditions":488,"keywords":491,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":76},"100117941","use-of-existing-fibroblast-cells-to-convert-to-induced-pluripotent-stem-cells-100117941","NCT00801372","Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells","Inclusion Criteria:\n\n* healthy, older than 18\n\nExclusion Criteria:\n\n* non healthy, younger than 18",{"count":76,"type":22},"Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.\n\nThe major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.",[489,490],"Pregnant, Healthy Females","Healthy Male Newborns",[492,493,494],"termination of pregnancy","surgical circumcision","umbilical cord",{"date":474,"type":42},{"date":497,"type":42},"2008-11",{"date":128,"type":22},{"name":48,"class":49},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":58,"sex":507,"minAge":19,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":514,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":76},"100513303","the-genital-microbiome-of-male-partners-of-women-with-recurrent-bv-undergoing-vaginal-microbiome-transplantation-100513303","NCT05963711","The Genital Microbiome of Male Partners of Women with Recurrent BV Undergoing Vaginal Microbiome Transplantation","The Penile Microbiome in Partners of Women with Recurrent BV and Its Response to Decolonization Protocol","Inclusion Criteria:\n\n* The subject has s female partner who participates in VMT study ( NCT04517487).\n* The subject is defined by the woman as her male regular partner.\n* Willing to use a condom as instructed by the protocol.\n* Willing to comply with decolonization protocol.\n\nExclusion Criteria:\n\n* A known skin disease involving the penile skin.\n* A known sensitivity to chlorhexidine gluconate\n* Any of the partners (female\u002Fmale) has more than one sexual partner.","MALE",{"count":140,"type":22},[25],"There is strong observational evidence that sexual activity plays a key role in Bacterial Vaginosis (BV) acquisition and recurrence. Microbiological data support the contribution of sexual transmission to the pathogenesis of BV through the exchange of BV-associated bacteria (BVAB) between sexual partners.\n\nAlthough BV epidemiology strongly suggests sexual transmission, treatment of sexual partners is not recommended, based on prior treatment studies of male partners of women with recurrent BV, which showed no benefit with male treatment. Nevertheless, male condom use is highly protective against recurrent BV.\n\nThis study aims to evaluate the male-partner's genital microbiome as a potential source of BV-recurrence in women undergoing vaginal microbiota transplantation (NCT04517487), and whether disinfection can eliminate BV-associated penile microbiome.",[512,513],"Bacterial Vaginosis","Microbial Colonization",[515,516,517,518],"Penile microbiome","Vaginal microbiome transplant","Male partners","Bacterial vaginosis","2025-03-15",{"date":474,"type":42},{"date":522,"type":42},"2022-10-17",{"date":524,"type":22},"2026-06",{"name":48,"class":49},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":58,"sex":18,"minAge":169,"maxAge":285,"enrollmentInfo":533,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":76},"100488483","vaginal-microbiome-and-hpv-pre-malignant-and-cervical-dysplasia-100488483","NCT05640700","Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia","Assessing Personalized Vaginal Microbiome Contributions to HPV-driven Pre-malignant and Malignant Cervical Cancer","Inclusion Criteria:\n\n* Age 25-70\n* Attended the clinic for a Pap smear or colposcopy\n\nExclusion Criteria:\n\n* Patient does not approve sample collection\n* Usage of antibiotics in the month prior to clinic visit\n* Usage of any vaginal preparation or medication in the week prior to sample collection (anti-fungal, spermicides, lubricant etc.)\n* Menstruation\n* Pregnancy",{"count":534,"type":22},90,"In this study, the investigators will prospectively collect, analyze and integrate information regarding vaginal microbiome composition and HPV presence in women with cervical pathologies (high-grade CIN and CC) and controls, to construct a large dataset from patients with pre-cancerous cervical lesions and healthy women, to evaluate the personalized contribution of the vaginal microbiome to the CIN-CC sequence.",[537,538,539,540],"Human Papilloma Virus","Vaginal Flora Imbalance","Cancer Cervix Uterus","Cervical Dysplasia",{"date":474,"type":42},{"date":543,"type":42},"2022-11-09",{"date":221,"type":22},{"name":48,"class":49},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":113,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":562,"locationsCount":76},"100402225","vaginal-microbiome-transplantation-for-recurrent-bacterial-vaginosis-100402225","NCT04517487","Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis","Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis-A Placebo, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Ages 18-50\n* Recurrent BV, defined as ≥4 symptomatic episodes of BV during the last year, who require maintenance antibiotic treatment (twice weekly) in order to remain symptom-free, or if they experienced recurrence of BV in ≤ 2 months following antibiotic treatment, with a documented history of recurrent BV in the last year.\n* Patients are otherwise healthy.\n* Contraception use\n\nExclusion Criteria:\n\n* Pregnancy or a planned pregnancy in the upcoming year\n* Infection with HIV.\n* Immunodeficiency status.",{"count":140,"type":22},[25],"Vaginal Microbiome Transplantation (VMT) may be beneficial in treating the most severe cases of recurrent and antibiotics-nonresponsive cases of BV. Recently, we completed a preliminary study in which we treated patients with recurrent and antibiotics-non-responsive, intractable BV, with VMT from healthy donors \\[Lev-Sagie, Nature Medicine 2019\\]. Four VMT recipients in this preliminary study featured a significant improvement of both clinical symptoms and dysbiotic vaginal microbiome composition and function, which persisted over a long follow-up period, while one recipient featured a partial remission.\n\nThe proposed study is designed as a placebo, randomized controlled trial, and is aimed to further assess whether VMT may serve as a viable option in symptomatic, intractable BV. In the suggested study, we plan to compare transplantation of: 1) vaginal fluid from healthy donors, and 2) autologous transplantation, of the patient's own vaginal fluid.",[557],"Bacterial Vaginoses",{"date":474,"type":42},{"date":560,"type":42},"2020-08-20",{"date":161,"type":22},{"name":48,"class":49},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":58,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":76},"100385983","characterization-of-vaginal-urinary-and-fecal-microbiomes-in-women-with-recurrent-urinary-tract-infections-100385983","NCT04305808","Characterization of Vaginal, Urinary and Fecal Microbiomes in Women with Recurrent Urinary Tract Infections","Patients' inclusion criteria:\n\n* Menopausal status\n* Two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year Patients' exclusion criteria\n* Neurogenic bladder condition\n* Known immunodeficiencies\n* Usage of antibiotics or probiotics within the previous month\n* Known renal calculi or anatomic malformations\n\nControl subjects- Inclusion criteria:\n\n* Menopausal status\n* Sterile urine cultures, normal urinalysis, and negative sexually-transmitted PCR urine assay\n\nControl subjects- Exclusion criteria:\n\n\\- A prior history of UTIs or other urologic abnormalities.",{"count":570,"type":22},40,"The objectives are to evaluate whether variations in vaginal and\u002For urinary and\u002For fecal microbiome predispose postmenopausal women to recurrent cystitis. This will be explored using comparison of microbiome profiles between those with recurrent UTI compared to age-matched women without recurrent UTI.",[573,574],"Urinary Tract Infections","Menopause",{"date":474,"type":42},{"date":577,"type":42},"2021-08-01",{"date":221,"type":22},{"name":48,"class":49},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":111,"minAge":588,"maxAge":589,"enrollmentInfo":590,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":605},"100549490","severe-covid-19-infection-in-children-presenting-to-eds-in-israel-and-england-100549490","NCT06434701","Severe COVID-19 Infection in Children Presenting to EDs in Israel and England","Severe COVID-19 Infection in Children Presenting to Emergency Departments in Israel and England: A Prospective Multicenter Study","SPICE","Inclusion Criteria:\n\n1. SACI\n\n   Patients aged 16 years or younger with a positive COVID-19 PCR nasopharyngeal swab testing or bronchoalveolar sample who meet the definition of SACI:\n   * Receive oxygen via low-flow nasal cannula or oxygen mask, high-flow nasal cannula, bilevel or continuous positive airway pressure machine, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) Or\n   * Admitted to ICU\n2. MIS-C Patients aged 16 years or younger diagnosed with MIS-C","0 Years","16 Years",{"count":591,"type":22},500,[25],"Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.\n\nThe objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).\n\nA prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.",[595,596],"COVID-19","Inflammatory Response","2025-03-11",{"date":599,"type":42},"2025-03-14",{"date":601,"type":42},"2024-09-30",{"date":603,"type":22},"2026-08-31",{"name":48,"class":49},6,{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":58,"sex":111,"minAge":19,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":76},"100123502","development-of-ips-from-donated-somatic-cells-of-patients-with-neurological-diseases-100123502","NCT00874783","Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases","Derivation of Induced Pluripotent Stem Cells from Somatic Cells Donated by Patients with Neurological Diseases for the Study of the Pathogenesis of the Disorders and Development of Novel Therapies","Inclusion Criteria:\n\n* Donors suffering from different (specified) neurodegenerative disorders scheduled to undergo surgery for medical reasons or will donate a single or a few hairs--to be removed intact from the scull or other areas in the body.\n* Healthy donors scheduled to undergo surgery for medical reasons or will donate a single or a few hairs--to be removed intact from the scull or other areas in the body.\n\nExclusion Criteria:\n\n* None",{"count":259,"type":22},"Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5). The iPS cells seem to share many properties with human embryonic stem cells.\n\nInduced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.\n\nThe major goal of the project is to develop human iPS cells from cell cultures from skin biopsies or the patient's hair. The iPS cells will be developed primarily for modeling diseases and drug discovery as well as basic research, and for developing the technology that may eventually allow the use of iPS cells for future transplantation therapy. The iPS cells developed in the course of this application are not intended for use in transplantation therapy. Future development of iPS cells for clinical transplantation therapies will be subjected to the appropriate authorization by ethical and regulatory committees.",[616],"Neurodegenerative Disorders",[618,619,620,621,622,623,624,625,626,627],"Amyotrophic Lateral Sclerosis","Familial Dysautonomia","Parkinson's Disease","Alzheimer's Disease","Age Related Macular Degeneration","Retinitis Pigmentosa","Huntington's Disease","Machado - Joseph Disease","SMA - Spinal Muscular Atrophy","Ataxia Telangiectasia","2025-03-03",{"date":630,"type":42},"2025-03-04",{"date":632,"type":42},"2009-04",{"date":128,"type":22},{"name":48,"class":49},""]